Non-Viral Chimeric Antigen Receptor (CAR) Immunotherapy Platform Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Non-Viral Chimeric Antigen Receptor (CAR) Immunotherapy Platform General Information

Description

Rights of an allogeneic, non-viral chimeric antigen receptor (CAR) technology platform. Non-viral chimeric antigen receptor (CAR) technology platform which leverages Cytokine-Induced Killer (C.I.K.) cells as immune effector cells, is developed at University of Milano-Bicocca.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Piazza dell'Ateneo Nuovo, 1
  • 20126 Milan
  • Italy
Primary Industry
Buildings and Property
Other Industries
Other Healthcare Technology Systems
Acquirer
Formula Pharmaceuticals
Vertical(s)
TMT, Life Sciences
Corporate Office
  • Piazza dell'Ateneo Nuovo, 1
  • 20126 Milan
  • Italy

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Non-Viral Chimeric Antigen Receptor (CAR) Immunotherapy Platform Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Non-Viral Chimeric Antigen Receptor (CAR) Immunotherapy Platform‘s full profile, request access.

Request a free trial

Non-Viral Chimeric Antigen Receptor (CAR) Immunotherapy Platform FAQs

  • Where is Non-Viral Chimeric Antigen Receptor (CAR) Immunotherapy Platform headquartered?

    Non-Viral Chimeric Antigen Receptor (CAR) Immunotherapy Platform is headquartered in Milan, Italy.

  • What industry is Non-Viral Chimeric Antigen Receptor (CAR) Immunotherapy Platform in?

    Non-Viral Chimeric Antigen Receptor (CAR) Immunotherapy Platform’s primary industry is Buildings and Property.

  • Is Non-Viral Chimeric Antigen Receptor (CAR) Immunotherapy Platform a private or public company?

    Non-Viral Chimeric Antigen Receptor (CAR) Immunotherapy Platform is a Private company.

  • What is Non-Viral Chimeric Antigen Receptor (CAR) Immunotherapy Platform’s current revenue?

    The current revenue for Non-Viral Chimeric Antigen Receptor (CAR) Immunotherapy Platform is .

  • When was Non-Viral Chimeric Antigen Receptor (CAR) Immunotherapy Platform acquired?

    Non-Viral Chimeric Antigen Receptor (CAR) Immunotherapy Platform was acquired on 11-May-2015.

  • Who acquired Non-Viral Chimeric Antigen Receptor (CAR) Immunotherapy Platform?

    Non-Viral Chimeric Antigen Receptor (CAR) Immunotherapy Platform was acquired by Formula Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »